Posted by Michael Wonder on 27 Sep 2024
FDA grants fast track designation to PTC518 Huntington's disease program
26 September 2024 - PTC Therapeutics announced today that the FDA has granted fast track designation to the PTC518 program for the treatment of Huntington's disease.
PTC518 was discovered using PTC's innovative splicing platform, following the successful discovery and development of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy.
